Literature DB >> 19579072

Longitudinal myelitis associated with yellow fever vaccination.

M Chaves1, P Riccio, L Patrucco, J I Rojas, E Cristiano.   

Abstract

Severe adverse reaction to yellow fever (YF) vaccine includes the yellow fever vaccine-associated neurotropic disease. This terminology includes postvaccinal encephalitis, acute disseminated encephalomyelitis, and Guillain-Barré syndrome. The objective of this communication is to report a patient who received a YF vaccine in Argentina and subsequently developed longitudinal myelitis with a symptom that had previously gone unreported in the literature. A 56-year-old man began with progressive paraparesia, urinary retention, and constipation 48 h previous to admission. The patient received YF vaccine 45 days prior to the onset of the symptoms. There was no history of other immunization or relevant condition. MR of the spine showed longitudinal intramedullary hyperintense signal (D5-12) without gadolinium enhancement. A high concentration of YFV-specific IgM vaccine antibody was found in the cerebrospinal fluid (CSF). Serological tests for other flavivirus were negative. A diagnosis of longitudinal myelitis without encephalitis associated with YF vaccine was performed and symptoms improved 5 days later. This is the first report dealing with longitudinal myelitis as a serious adverse event associated with YF vaccination in which confirmation of the presence of antibodies in CSF was found. To date, it is also the first report with serological confirmation in Argentina and in South America. We consider that the present investigation will raise awareness in the region in the reporting of adverse events related to YF vaccine and improve our knowledge of adverse reactions to the vaccine.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19579072     DOI: 10.1080/13550280903062805

Source DB:  PubMed          Journal:  J Neurovirol        ISSN: 1355-0284            Impact factor:   2.643


  8 in total

1.  Viscerotropic and neurotropic disease following vaccination with the 17D yellow fever vaccine, ARILVAX.

Authors:  Scott Kitchener
Journal:  Vaccine       Date:  2004-06-02       Impact factor: 3.641

Review 2.  Understanding vaccine safety information from the Vaccine Adverse Event Reporting System.

Authors:  Frederick Varricchio; John Iskander; Frank Destefano; Robert Ball; Robert Pless; M Miles Braun; Robert T Chen
Journal:  Pediatr Infect Dis J       Date:  2004-04       Impact factor: 2.129

3.  The role of the Vaccine Adverse Event Reporting system (VAERS) in monitoring vaccine safety.

Authors:  John K Iskander; Elaine R Miller; Robert T Chen
Journal:  Pediatr Ann       Date:  2004-09       Impact factor: 1.132

4.  Adverse event reports following yellow fever vaccination.

Authors:  Nicole P Lindsey; Betsy A Schroeder; Elaine R Miller; M Miles Braun; Alison F Hinckley; Nina Marano; Barbara A Slade; Elizabeth D Barnett; Gary W Brunette; Katherine Horan; J Erin Staples; Phyllis E Kozarsky; Edward B Hayes
Journal:  Vaccine       Date:  2008-09-20       Impact factor: 3.641

5.  Neurologic disease associated with 17D-204 yellow fever vaccination: a report of 15 cases.

Authors:  Ann W McMahon; Rachel B Eidex; Anthony A Marfin; Michelle Russell; James J Sejvar; Lewis Markoff; Edward B Hayes; Robert T Chen; Robert Ball; M Miles Braun; Martin Cetron
Journal:  Vaccine       Date:  2006-11-27       Impact factor: 3.641

6.  Yellow fever vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2002.

Authors:  Martin S Cetron; Anthony A Marfin; Kathleen G Julian; Duane J Gubler; Donald J Sharp; Rachel S Barwick; Leisa H Weld; Robert Chen; Richard D Clover; Jaime Deseda-Tous; Victor Marchessault; Paul A Offit; Thomas P Monath
Journal:  MMWR Recomm Rep       Date:  2002-11-08

7.  Neurological adverse events temporally associated to mass vaccination against yellow fever in Juiz de Fora, Brazil, 1999-2005.

Authors:  Guilherme Côrtes Fernandes; Luiz Antonio Bastos Camacho; Marilia Sá Carvalho; Maristela Batista; Sonia Maria Rodrigues de Almeida
Journal:  Vaccine       Date:  2007-01-30       Impact factor: 3.641

8.  First recorded outbreak of yellow fever in Kenya, 1992-1993. I. Epidemiologic investigations.

Authors:  E J Sanders; A A Marfin; P M Tukei; G Kuria; G Ademba; N N Agata; J O Ouma; C B Cropp; N Karabatsos; P Reiter; P S Moore; D J Gubler
Journal:  Am J Trop Med Hyg       Date:  1998-10       Impact factor: 2.345

  8 in total
  10 in total

Review 1.  Immunizations and risk of multiple sclerosis: systematic review and meta-analysis.

Authors:  Mauricio F Farez; Jorge Correale
Journal:  J Neurol       Date:  2011-03-24       Impact factor: 4.849

2.  Transverse myelitis associated with yellow fever vaccination.

Authors:  Kyle D Bartol; Jose L Aguirre; Salvatore V Labruzzo; Russ P Henriet
Journal:  Proc (Bayl Univ Med Cent)       Date:  2019-03-26

3.  Neuromyelitis optica associated with yellow fever vaccination.

Authors:  Bruno Bertoli Esmanhotto; Isabella Moraes Rocha; Carolina Rodrigues Laranjeira Vilar; Rafael Follador Haluch; Thaís Pimenta Valença
Journal:  Acta Neurol Belg       Date:  2020-06-10       Impact factor: 2.396

Review 4.  Acute transverse myelitis following SARS-CoV-2 vaccination: a case report and review of literature.

Authors:  Erum Khan; Ashish K Shrestha; Mark A Colantonio; Richard N Liberio; Shitiz Sriwastava
Journal:  J Neurol       Date:  2021-09-05       Impact factor: 6.682

Review 5.  What Does the Future Hold for Yellow Fever Virus? (II).

Authors:  Raphaëlle Klitting; Carlo Fischer; Jan F Drexler; Ernest A Gould; David Roiz; Christophe Paupy; Xavier de Lamballerie
Journal:  Genes (Basel)       Date:  2018-08-21       Impact factor: 4.096

Review 6.  Vaccination in Multiple Sclerosis: Friend or Foe?

Authors:  Tobias Zrzavy; Herwig Kollaritsch; Paulus S Rommer; Nina Boxberger; Micha Loebermann; Isabella Wimmer; Alexander Winkelmann; Uwe K Zettl
Journal:  Front Immunol       Date:  2019-08-07       Impact factor: 7.561

7.  The Attenuated Live Yellow Fever Virus 17D Infects the Thymus and Induces Thymic Transcriptional Modifications of Immunomodulatory Genes in C57BL/6 and BALB/C Mice.

Authors:  Breno Luiz Melo-Lima; Danillo Lucas Alves Espósito; Benedito Antônio Lopes da Fonseca; Luiz Tadeu Moraes Figueiredo; Philippe Moreau; Eduardo Antonio Donadi
Journal:  Autoimmune Dis       Date:  2015-09-17

Review 8.  Find the right sample: A study on the versatility of saliva and urine samples for the diagnosis of emerging viruses.

Authors:  Matthias Niedrig; Pranav Patel; Ahmed Abd El Wahed; Regina Schädler; Sergio Yactayo
Journal:  BMC Infect Dis       Date:  2018-12-29       Impact factor: 3.090

Review 9.  A clinician's perspective on yellow fever vaccine-associated neurotropic disease.

Authors:  Elien Lecomte; Guy Laureys; Frederick Verbeke; Cristina Domingo Carrasco; Marjan Van Esbroeck; Ralph Huits
Journal:  J Travel Med       Date:  2020-11-09       Impact factor: 8.490

Review 10.  Early approval of COVID-19 vaccines: Pros and cons.

Authors:  Md Arifur Rahman; Md Sayeedul Islam
Journal:  Hum Vaccin Immunother       Date:  2021-07-20       Impact factor: 3.452

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.